NCT05979831View on ClinicalTrials.gov

A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

September 28, 2023

Primary Completion Date

January 6, 2025

Study Completion Date

January 6, 2025

Conditions
Netherton Syndrome
Interventions
DRUG

DS-2325a

Main Phase and Extension Phase: Loading IV dose followed by maintenance SC doses

OTHER

Placebo

Main Phase: IV infusion followed by SC doses

Trial Locations (1)

75012

Saint Louis Hospital, Paris

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY

NCT05979831 - A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome | Biotech Hunter | Biotech Hunter